Professor Claude Wischik
Chair in Mental Health (Clin)
- About
-
- Email Address
- c.m.wischik@abdn.ac.uk
- Office Address
TauRx Therapeutics Ltd
1st Floor, Sir Moir Lockhead Building
395 King Street
Aberdeen
AB24 5RP
United Kingdom
- School/Department
- School of Medicine, Medical Sciences and Nutrition
- Research
-
Research Overview
Molecular Neuropathology of Alzheimer's Disease, and in particular the therapeutic intervention of tau pathology
- Publications
-
Page 1 of 4 Results 1 to 25 of 100
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease
Alzheimer's Research & Therapy, vol. 16, 209Contributions to Journals: ArticlesRescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor hydromethylthionine
Cellular Signalling, vol. 121, 111269Contributions to Journals: ArticlesHydromethylthionine rescues synaptic SNARE proteins in a mouse model of tauopathies: interference by cholinesterase inhibitors
Brain Research Bulletin, vol. 212, 110955Contributions to Journals: ArticlesConsiderations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
Translational neurodegeneration, vol. 13, 25Contributions to Journals: Review articles- [ONLINE] DOI: https://doi.org/10.1186/s40035-024-00417-w
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/23668/1/s40035-024-00417-w.pdf
LETC inhibits α-Syn aggregation and ameliorates motor deficiencies in the L62 mouse model of synucleinopathy
European Journal of Pharmacology, vol. 970, 176505Contributions to Journals: ArticlesNeuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model
Cells, vol. 13, no. 7, 642Contributions to Journals: ArticlesAssays for the Screening and Characterization of Tau Aggregation Inhibitors
Tau Protein: Methods and Protocols. 2 edition, pp. 93-104, 12 pagesChapters in Books, Reports and Conference Proceedings: Chapters (Peer-Reviewed)- [ONLINE] DOI: https://doi.org/10.1007/978-1-0716-3629-9_5
Solubility of α-synuclein species in the L62 mouse model of synucleinopathy
Scientific Reports, vol. 14, 6239Contributions to Journals: ArticlesApathy-like behaviour in tau mouse models of Alzheimer’s disease and frontotemporal dementia
Behavioural Brain Research, vol. 456, 114707Contributions to Journals: ArticlesA Meta-Analysis on Presynaptic Changes in Alzheimer's Disease
Journal of Alzheimer's Disease, vol. 97, no. 1, pp. 145-162Contributions to Journals: ArticlesSignificant dose-dependent reduction in neurofilament light chain concentration in plasma with oral tau aggregation inhibitor hydromethylthionine mesylate
Alzheimer's Dementia, vol. 19, no. S24, e083153Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1002/alz.083153
Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants
International Journal of Molecular Sciences, vol. 24, no. 18, 13747Contributions to Journals: ArticlesMitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice
International Journal of Molecular Sciences, vol. 24, no. 13, 10810Contributions to Journals: ArticlesUtility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease: Systematic Review and Meta-Analysis
Cells, vol. 12, no. 8, 1184Contributions to Journals: Review articlesAn Additive-Free Model for Tau Self-Assembly
Methods in molecular biology (Clifton, N.J.), vol. 2551, pp. 163-188Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/978-1-0716-2597-2_12
- [ONLINE] View publication in Scopus
Solid-state NMR of paired helical filaments formed by the core tau fragment tau(297-391)
Frontiers in Neuroscience, vol. 16, 988074Contributions to Journals: ArticlesDityrosine Cross-links are Present in Alzheimer's Disease-derived Tau Oligomers and Paired Helical Filaments (PHF) which Promotes the Stability of the PHF-core Tau (297–391) In Vitro
Journal of Molecular Biology, vol. 434, no. 19, 167785Contributions to Journals: ArticlesOral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate
Journal of Prevention of Alzheimer's Disease, vol. 9, pp. 780-790Contributions to Journals: ArticlesGlutamatergic transmission and receptor expression in the synucleinopathy h-α-synL62 mouse model: Effects of hydromethylthionine
Cellular Signalling, vol. 97, 110386Contributions to Journals: ArticlesStructural Identification of Individual Helical Amyloid Filaments by Integration of Cryo-Electron Microscopy-Derived Maps in Comparative Morphometric Atomic Force Microscopy Image Analysis
Journal of Molecular Biology, vol. 434, no. 7, 167466Contributions to Journals: ArticlesHMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine
Biomedicines, vol. 10, no. 4, 867Contributions to Journals: ArticlesCrossed cerebellar diaschisis in Alzheimer's disease
Nuclear Medicine Communications, vol. 43, no. 4, pp. 423-427Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1097/MNM.0000000000001531
- [ONLINE] View publication in Scopus
Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine
Journal of Neurochemistry, vol. 160, pp. 172-184Contributions to Journals: ArticlesDegeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia
Brain Communications, vol. 3, no. 4, fcab241Contributions to Journals: ArticlesLong-term hydromethylthionine treatment is associated with delayed clinical onset and slowing of cerebral atrophy in a pre-symptomatic P301S MAPT mutation carrier
Journal of Alzheimer's Disease, vol. 83, no. 3, pp. 1017-1023Contributions to Journals: Articles